B. Floccard, N. Javaud, A. Deroux, I. Boccon-gibod, O. Fain et al., Diagnosis and treatment of upper airway oedema caused by acute angio-oedema in the emergency department: a French consensus statement, Reshef A, Kidon M, Leibovich I. The Story of Angioedema: from Quincke to Bradykinin, vol.24, pp.121-160, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01813353

H. Quincke, Concerning the acute localized oedema of the skin, Mschr Prakt Dermatol, vol.1882, pp.160-169

P. Strübing, Uber acutes (angioneurotisches) Odem, Zeitschr F Klin Med, vol.9, p.381, 1995.

W. Osler, T. Zuberbier, W. Aberer, R. Asero, A. Latiff et al., Hereditary angio-neurotic oedema, Am J Med Sci, vol.95, pp.362-369, 1888.

E. The, M. Maurer, M. Magerl, I. Ansotegui, E. Aygören-pürsün et al., Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update, Allergy, vol.7, pp.1575-1596, 2018.

A. P. Kaplan, M. W. Greaves, and . Angioedema, J Am Acad Dermatol, vol.53, pp.373-88, 2005.

M. Ferrer, T. Zuberbier, M. Balke, M. Worm, G. Edenharter et al., Epidemiology of urticaria: a representative cross-sectional population survey, Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykininmediated angioedema: a systematic investigation of epidemiological studies, vol.19, p.50, 2005.

F. Psarros, N. Koutsostathis, E. Farmaki, M. G. Speletas, and A. E. Germenis, Hereditary angioedema in Greece: the first results of the greek hereditary angioedema registry, Orphanet J Rare Dis, vol.13, p.73, 2018.

K. E. Binkley, H. Davis-a-3rd-;-farkas, I. Martinez-saguer, K. Bork, T. Bowen et al., International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency, Int Arch Allergy Immunol, vol.164, pp.300-313, 2000.

C. Peretti, R. Y. Lin, A. G. Cannon, A. D. Teitel, N. J. Brown et al., Black Americans have an increased rate of angiotensin convertase inhibitor-associated angioedema, Boccon-Gibod I, Bouillet L. Angioedema and urticaria, vol.19, pp.650-654, 1990.

P. J. Busse, T. Smith, F. Histaminergic-angioedema-;-hacard, A. Nosbaum, B. Bensaid et al., Immunol Allergy Clin North Am, vol.3, pp.467-481, 2017.

H. Nosbaum, A. Augey, F. Nicolas, J. F. Bérard, F. Pathophysiology et al., Classification of anti-Fc!RI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity, Mathelier-Fusade P, Vermeulen C, Leynadier F. Responsibility of food in exercise-induced anaphylaxis: 7 cases, vol.44, pp.958-961, 1999.

J. Mcfadden, S. Kohli, V. K. Mahajan, B. S. Rana, K. S. Mehta et al., Immunologic contact urticaria, Immunol Allergy Clin North Am, vol.34, pp.157-67, 2014.

, Clinicoepidemiologic Features of Chronic Urticaria in Patients with versus without

S. Brown, K. E. Blackmean, R. Heddle, E. Toubi, A. Kessel et al., The EAACI/GA/LEN/EDF/WAO guideline for the definition, classification, diagnosis, and ma-nagement of urticaria: the 2013 revision and update, Subclinical Helicobacter pylori Infection: A Cross-Sectional Study of 150 Patients, vol.175, pp.330-371, 1962.

V. Donaldson, R. R. Evans, A. Siltari, R. Korpela, H. Vapaatalo et al., A biochemical abnormality in hereditary angioneurotic edema : absence of serum inhibitor of C'1-esterase, SERPING1 mutations in 59 families with hereditary angioedema, vol.35, pp.18-27, 1963.

A. Agostoni, E. Aygoren-pursun, K. E. Binkley, A. Blanch, K. Bork et al., Hereditary and acquired angioedema: problems and progress: proceedings of the third C1esterase inhibitor deficiency workshop and beyond, Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema, vol.106, pp.2273-2280, 2000.

C. Saule, I. Boccon-gibod, O. Fain, G. Kanny, G. Plu-bureau et al., Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant, Ponard D. Hereditary angioedema biological diagnosis, vol.54, pp.274-81, 2003.

O. Fain, D. Gobert, C. A. Khau, A. Mekinian, and N. Javaud,

M. D. Tarzi, A. Hickey, T. Förster, M. Mohammadi, H. Longhurst et al., An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema, Clin Exp Immunol, vol.44, p.70140, 2007.

T. Caballero, H. Farkas, L. Bouillet, T. Bowen, A. Gompel et al., International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency, Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P, vol.121, pp.308-320, 2008.

T. Bowen, M. Cicardi, H. Farkas, K. Bork, H. J. Longhurst et al., , 2010.

A. S. Grumach, M. E. Ceccon, R. Rutz, A. Fertig, M. Kirschfink et al., A systematic review of the literature of the three related disease entities cheilitis granulomatosa, orofacial granulomatosis and Melkersson-Rosenthal syndrome, Launay D. Angioedema: differential diagnosis, vol.6, pp.1493-1502, 1985.

A. Licari, A. Marseglia, S. Caimmi, R. Castagnoli, T. Foiadelli et al., Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria, J Eur Acad Dermatol Venereol, vol.115, pp.365-72, 2000.

H. A. Sampson, A. Muñoz-furlong, R. L. Campbell, N. F. Adkinson, and S. A. Bock, Multiple mechanisms of inhibition of IgE-and mast cell-dependent cutaneous inflammation in the mouse, J Immunol, vol.154, pp.1391-1399, 1995.

A. Branum, Treatment of Refractory Chronic Spontaneous Urticaria with Adalimumab, Rituximab in Refractory Chronic Spontaneous Urticaria: An Encouraging Therapeutic Approach, vol.129, pp.524-525, 2017.

V. K. Sharma, S. Singh, M. Ramam, M. Kumawat, and R. Kumar, A randomized placebo-controlled double-blind pilot study of methotrexate in the treatment of H1, Skin Pharmacol Physiol, vol.31, pp.184-187, 2018.

, antihistamine-resistant chronic spontaneous urticaria, Indian J Dermatol Venereol Leprol, vol.80, pp.122-130, 2014.

M. Maurer, M. Metz, R. Brehler, U. Hillen, T. Jakob et al.,

M. Metz, A. Schütz, K. Weller, M. Gorczyza, S. Zimmer et al., Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence, J Allergy Clin Immunol, vol.141, pp.638-649, 2018.

U. Bullerkotte, D. Wieczorek, A. Kapp, and B. Wedi, Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial, J Allergy Clin Immunol, vol.140, pp.931-932, 2010.

M. Metz, P. Bergmann, T. Zuberbier, M. Maurer, O. Guzelbey et al., Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy, Allergy, vol.63, pp.247-249, 2008.

C. Bindslev-jensen and P. S. Skov, Efficacy of omalizumab in delayed pressure urticaria: a case report, Allergy, vol.63, pp.138-139, 2008.

M. Maurer, A. Schutz, K. Weller, N. Schoepke, A. Peveling-oberhag et al., Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: A pilot study, J Allergy Clin Immunol, vol.140, pp.302-305, 2008.

G. Gualdi, P. Monari, M. T. Rossi, S. Crotti, and P. G. Calzavara-pinton, Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis

, Br J Dermatol, vol.166, pp.1373-1374, 2012.

M. Magerl, S. Philipp, M. Manasterski, M. Friedrich, M. Maurer et al., Breh-ler R. Delayed pressure urticariadapsone heading for first-line therapy?, J Allergy Clin Immunol, vol.119, pp.908-912, 2000.

F. Aubin, R. Porcher, M. Jeanmougin, F. Leonard, C. Bedane et al., Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study, Edstrom DW, Ros AM. Cyclosporin A therapy for severe solar urticaria, vol.71, pp.948-953, 2014.

E. Kocatürk, M. Maurer, M. Metz, C. Grattan, B. Balbino et al., Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and metaanalysis, Photoder-matol Photoimmunol Photomed, vol.13, pp.775-788, 1997.

G. , Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®), Ann Allergy Asthma Immunol, vol.135, pp.149-54, 2010.

K. Bork, J. Frank, B. Grundt, P. Schlattmann, J. Nussberger et al., C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency, Farkas H, Varga L. Human Plasma-Derived, Nanofiltered, vol.13, pp.109-123, 2012.

T. Caballero, A. Zanichelli, W. Aberer, M. Maurer, H. J. Longhurst et al., Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study, Gelfand JA, vol.119, pp.281-288, 1976.

C. Wintenberger, I. Boccon-gibod, D. Launay, O. Fain, G. Kanny et al., Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients, Clin Exp Immunol, vol.7, pp.112-119, 2014.

L. Bouillet, A. Lehmann, A. Gompel, I. Boccon-gibod, D. Launay et al., The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women, A random double-blind cross-over study, vol.192, pp.1034-1039, 1972.

M. Pedrosa, 175 : Farkas H. Pharmacological Management of Hereditary Angioedema with C1Inhibitor Deficiency in Pediatric Patients, J Investig Allergol Clin Immunol, vol.23, pp.135-151, 2013.

T. Caballero, J. Canabal, D. Rivero-paparoni, R. Cabanas, H. Farkas et al., Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant, Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema, vol.5, pp.29-36, 2014.

D. Herman, Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema, Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc, vol.38, pp.520-524, 2011.

, Management of angiotensin-converting enzyme inhibitor-related angioedema: Recommendations from the French national centre for angioedema, Rev Med Interne, vol.34, pp.209-222, 2013.

S. M. Lipski, G. Casimir, M. Vanlommel, M. Jeanmaire, P. Dolhen et al., The use of plasma-derived complement C1-esterase inhibitor concentrate (Berinert) in the treatment of angiotensin converting enzyme-inhibitor related angioedema, Angiotensinconverting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert®): about one case and review of the therapeutic arsenal, vol.3, pp.429-462, 2011.

D. Corso, I. Puxeddu, I. Sardano, E. Geraci, S. Breggia et al., Successful treatment of refractory idiopathic angioedema with omalizumab: review of the literature and function of IgE in angioedema, J Investig Allergol Clin Immunol, vol.108, pp.399-402, 2012.

K. Idiopathic-non-histaminergic-angioedema-;-bork, J. Hardt, G. Witzke, E. Arroabarren, E. M. Lasa et al., Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency, J Allergy Clin Immunol, vol.37, pp.692-697, 2012.

R. Muñoz-cano, J. Sanchez-lopez, J. Bartra, A. Valero, E. Bidat et al., High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria, J Eur Acad Dermatol Venereol, vol.22, pp.557-61, 2003.

, Annexe 3 : score d'activité de l'urticaire sur 7 jours

. Nom and . Patient,

, Annexe 6 : Questionnaire de qualité de vie de l'urticaire chronique

E. Selon, C. Bidat, and . Feuillet,

, Poids : Dès les premiers signes, appeler le SAMU (15 ou 112 sur portable), pratiquer le protocole suivant et prévenir les parents : Noter la date, l'heure des signes et des médicaments donnés

, Annexe 14 : lettre d'information médecin traitant, angio-oedème histaminique Patient

. .. Cher-confrère-;-le, est sujet(te) à des angio-oedèmes histaminiques de type, Votre patient(e)

. , Un oedème localisé, sans signe d'anaphylaxie, associée ou non à une urticaire superficielle, nécessitera la prise d'un comprimé d'antihistaminique

.. .. ,

, En cas de signe d'anaphylaxie (! grade 2) et / ou d'angio-oedème des

.. .. Un-traitement-de-fond-par,

. , Je reste à votre disposition pour tout renseignement complémentaire. Veuillez agréer, cher confrère, l'expression de mes salutations distinguées